Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Initial Dose:** 5 mg twice daily.
* **Titration:** Increase dose by 5-10 mg every week based on clinical response and tolerability, up to a maximum of 20 mg twice daily.
* **Maintenance Dose:** Typically 10-20 mg twice daily.
## Pediatric Dosing (2 to <10 years of age)
* **Initial Dose:** 5 mg once daily.
* **Titration:** Increase dose by 2.5-5 mg every week based on clinical response and tolerability.
* **Maintenance Dose:** Typically 5-10 mg twice daily, not to exceed 0.5-1 mg/kg/day in divided doses.
## Pediatric Dosing (10 years of age and older)
Dosing is the same as adult dosing.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment recommendations, but start with lower doses and titrate slowly.
* **Renal Impairment:** Use with caution. No specific dose adjustment recommendations, but start with lower doses and titrate slowly.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic insufficiency.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, drooling, fatigue, pyrexia, and upper respiratory tract infection. Serious adverse effects include severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), respiratory depression, and paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines):** Increased risk of sedation and respiratory depression.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is a substrate of CYP3A4. Coadministration with strong CYP3A4 inhibitors may increase clobazam levels, and coadministration with strong CYP3A4 inducers may decrease clobazam levels.
* **Antiepileptic Drugs (AEDs):** Potential for additive CNS depression.
## Monitoring
* Monitor for efficacy in seizure control.
* Monitor for adverse effects, particularly somnolence, behavioral changes, and signs of respiratory depression.
* Monitor for signs and symptoms of SCARs.
* Monitor for drug interactions, especially with concomitant CNS depressants or CYP3A4 affecting agents.
## Clinical Pearls
* Clobazam should be initiated at a low dose and gradually increased to minimize adverse effects.
* Patients should be advised against operating heavy machinery or engaging in hazardous activities until they know how clobazam affects them.
* Abrupt discontinuation can lead to withdrawal symptoms. Taper the dose slowly if discontinuing.
* Clobazam is a Schedule IV controlled substance.
***
**Disclaimer:** This information is intended for healthcare professionals and is based on available prescribing information. It is not exhaustive and does not replace the need for critical clinical judgment. Always consult the most current prescribing information and relevant guidelines before making treatment decisions.
